STAT+: PepGen says early trial for muscular dystrophy drug looks promising

Coverage, in order

1. 1d ago
   
   first STAT News indie study n=100,000

   STAT+: PepGen says early trial for muscular dystrophy drug looks promising

   The biotech PepGen said Tuesday that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a muscle disorder that affects over 100,000 people in the U.S. and Europe. PepGen is a latecomer to the fight to treat myotonic dystrophy type 1 (DM1), a…

2. 1d ago
   
   BioPharma Dive indie

   PepGen soars on promising early data for muscular dystrophy drug

   While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.